These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Can mesenchymal stem cells reduce vulnerability of dopaminergic neurons in the substantia nigra to oxidative insult in individuals at risk to Parkinson's disease? Datta I; Bhonde R Cell Biol Int; 2012 Jul; 36(7):617-24. PubMed ID: 22417707 [TBL] [Abstract][Full Text] [Related]
24. Analysis of the glucocerebrosidase gene in Parkinson's disease. Sato C; Morgan A; Lang AE; Salehi-Rad S; Kawarai T; Meng Y; Ray PN; Farrer LA; St George-Hyslop P; Rogaeva E Mov Disord; 2005 Mar; 20(3):367-70. PubMed ID: 15517592 [TBL] [Abstract][Full Text] [Related]
25. The MitoPark Mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons. Ekstrand MI; Galter D Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S185-8. PubMed ID: 20082987 [TBL] [Abstract][Full Text] [Related]
26. Quantitative expression proteomics and phosphoproteomics profile of brain from PINK1 knockout mice: insights into mechanisms of familial Parkinson's disease. Triplett JC; Zhang Z; Sultana R; Cai J; Klein JB; Büeler H; Butterfield DA J Neurochem; 2015 Jun; 133(5):750-65. PubMed ID: 25626353 [TBL] [Abstract][Full Text] [Related]
27. Protective action of recombinant neurturin on dopaminergic neurons in substantia nigra in a rhesus monkey model of Parkinson's disease. Li H; He Z; Su T; Ma Y; Lu S; Dai C; Sun M Neurol Res; 2003 Apr; 25(3):263-7. PubMed ID: 12739234 [TBL] [Abstract][Full Text] [Related]
28. Overexpression of α-synuclein simultaneously increases glutamate NMDA receptor phosphorylation and reduces glucocerebrosidase activity. Yang J; Hertz E; Zhang X; Leinartaité L; Lundius EG; Li J; Svenningsson P Neurosci Lett; 2016 Jan; 611():51-8. PubMed ID: 26610904 [TBL] [Abstract][Full Text] [Related]
29. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons. Hill WD; Arai M; Cohen JA; Trojanowski JQ J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049 [TBL] [Abstract][Full Text] [Related]
30. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease. Zuo L; Motherwell MS Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870 [TBL] [Abstract][Full Text] [Related]
31. Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders. Walter U; Hoeppner J; Prudente-Morrissey L; Horowski S; Herpertz SC; Benecke R Brain; 2007 Jul; 130(Pt 7):1799-807. PubMed ID: 17329323 [TBL] [Abstract][Full Text] [Related]
32. Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson's disease pathogenesis. Licker V; Turck N; Kövari E; Burkhardt K; Côte M; Surini-Demiri M; Lobrinus JA; Sanchez JC; Burkhard PR Proteomics; 2014 Mar; 14(6):784-94. PubMed ID: 24449343 [TBL] [Abstract][Full Text] [Related]
33. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. Duan W; Mattson MP J Neurosci Res; 1999 Jul; 57(2):195-206. PubMed ID: 10398297 [TBL] [Abstract][Full Text] [Related]
34. In vivo protein targets for increased quinoprotein adduct formation in aged substantia nigra. Yu G; Liu H; Zhou W; Zhu X; Yu C; Wang N; Zhang Y; Ma J; Zhao Y; Xu Y; Liao L; Ji H; Yuan C; Ma J Exp Neurol; 2015 Sep; 271():13-24. PubMed ID: 25956828 [TBL] [Abstract][Full Text] [Related]
35. Experience in Genetic Counseling for den Heijer JM; van Hilten JJ; Kievit AJA; Bonifati V; Groeneveld GJ Mov Disord Clin Pract; 2021 Jan; 8(1):33-36. PubMed ID: 33426156 [No Abstract] [Full Text] [Related]
36. The association between lysosomal protein glucocerebrosidase and Parkinson's disease. Eur Rev Med Pharmacol Sci; 2015; 19(2):179. PubMed ID: 25683925 [No Abstract] [Full Text] [Related]
37. Biochemical consequences of Yoon J; Lee CY; V Schapira AH Neural Regen Res; 2024 Apr; 19(4):725-727. PubMed ID: 37843204 [No Abstract] [Full Text] [Related]
38. New glucocerebrosidase antibodies can advance research in the field of neurodegenerative disorders. Ma C; Rytel K; Chen Y; Sidransky E Neural Regen Res; 2025 Apr; 20(4):1085-1086. PubMed ID: 38989943 [No Abstract] [Full Text] [Related]
39. Plasma oligomeric alpha-synuclein is associated with glucocerebrosidase activity in Gaucher disease. Nuzhnyi E; Emelyanov A; Boukina T; Usenko T; Yakimovskii A; Zakharova E; Pchelina S Mov Disord; 2015 Jun; 30(7):989-91. PubMed ID: 25962734 [TBL] [Abstract][Full Text] [Related]
40. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons. Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]